Poster 114: Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL

Andrew Blumenfeld: Consulting fees or other remuneration (payment) - Allergan, Avanir, Teva, Pernix, Supernus, Depomed, Dentex, Zosano Pharma, GLG, Guidepoint, Autodigest
Source: PM and R - Category: Rehabilitation Authors: Source Type: research

Related Links:

This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
“We are placing a spotlight on the fact that air pollution isn’t just a problem on our streets, but in our homes too. You can’t just close your door and shut out air pollution.” says Chris Large from Global Action Plan after their study found that indoor air is 3.5 times more polluted than the air outside. This 2019 study measured polluting nanoparticles in four British towns and cities in- and outdoors as well. At one point they even found a family living in pollution levels 560 times higher than the pollution level on the street. According to another research, people spend approximately 90 per...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine Healthcare Design digital health digital technology indoor air quality Source Type: blogs
What medication is associated with this patient’s presentation? A 41-year-old male patient presents to the emergency department with dyspnea, headache, vomiting, and weakness. He had a kidney transplant nine years ago, and has been on a stable anti-rejection regimen. He has allergies to ciprofloxacin and trimethoprim-sulfamethoxazole. Physical examination reveals gray-blue discoloration of the nose, fingers, and toes. A chest X-ray and ECG are both unremarkable. Arterial blood gas... Dyspnea And Skin Discoloration In A Transplant Patient — What’s The Cause?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Educational Quizzes and Case Studies Forum Source Type: forums
ConclusionCNS disease is a severe but rare complication in CVID disorders, particularly affecting patients with other noninfectious disease symptoms. Diagnostic evaluation needs to rule out infectious causes by all means; a genetic evaluation is recommended given the high probability of an underlying monogenic disorder. Possible treatment consists of steroids with yet to be determined optimal maintenance therapy in case of relapse.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
FDA OKs Ubrelvy as First Oral Gepant for Migraine Treatment Migraine headache is a neurological disease with incapacitating symptoms that impacts 31 million Americans. In response, this month the FDA approved Ubrelvy (ubrogepant) from Allergan for...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
(CNN) — The US Food and Drug Administration on Monday announced the approval of a drug called ubrogepant for the acute treatment of migraine, which could be a new option for people who can’t take or don’t respond to migraine medications currently on the market. The drug will be sold under the name Ubrelvy by the pharmaceutical company Allergan. It is considered effective for migraine with or without aura, referring to the sensory or visual disturbances that occur among roughly a third of migraine sufferers. “Ubrelvy represents an important new option for the acute treatment of migraine in adults, as...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Syndicated CBSN Boston FDA Migraines Source Type: news
The U.S. Food and Drug Administration said on Monday it had approved Allergan Plc's drug for relieving migraine headaches after their onset.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
DUBLIN, Dec. 23, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Ubrelvy (ubrogepant) for the acute treatment of migraine with or without...
Source: - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
ConclusionsOne in four U.S. children with epilepsy has depression and/or anxiety. Therefore, physicians should consider the various factors that are related to depression and anxiety in children with epilepsy so that at-risk children can be screened and managed appropriately.
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
In this study, drug side effects in patients who were followed up with a rheumatic disease and treated with parenteral administration methods were evaluated. The drug side effects in children who were followed up with a rheumatic disease and treated with parenteral treatments between 2010 and 2019 were recorded, retrospectively. All parenteral treatments are applied by a clinical nurse specialist (CNS) who is experienced in pediatric rheumatology for 10 years. Four hundred and thirteen patients were evaluated in this study. The mean age was 12.09  ± 5.05 years. Most of them were diagnosed with juv...
Source: Rheumatology International - Category: Rheumatology Source Type: research
More News: Allergy | Headache | Migraine | Pharmaceuticals | Study